查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029菸鹼醯胺嘌呤二核甘酸的全球市場
市場調查報告書
商品編碼
1169029

2022-2029菸鹼醯胺嘌呤二核甘酸的全球市場

Global Nicotinamide Adenine Dinucleotide Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 96 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

菸鹼醯胺嘌呤二核甘酸是一種□啶核甘酸，是細胞的重要輔□和底物，包括 DNA 修復、表觀遺傳基因調控、細胞內鈣信號傳導和免疫功能。 它由兩個核甘酸、一個腺嘌呤鹼基和一個煙□胺鹼基組成。 NAD 通常由兩種類型的核甘酸組成，即腺嘌呤鹼基和煙□胺鹼基。 NAD通常以氧化型和還原型兩種形式存在，簡稱NAD+和NADH。 NAD也可以作為一種重要的輔助抗衰老藥物。 現代生物學研究中最著名的NAD補充劑是NADH，一種延長細胞生命週期（抗衰老）的線粒體激素。 NAD+ 還主要用於糖酵解等分解代謝途徑，分解能量分子以產生 ATP。 所有活細胞在其呼吸過程中都使用輔□菸鹼醯胺嘌呤二核甘酸 (NAD)。

在預測期內 (2022-2029)，全球菸鹼醯胺嘌呤二核甘酸市場預計將以 11.25% 的複合年增長率增長。

市場動態：消費者對 NAD 健康意識的提高推動了市場擴張

NAD 的使用讓人們更容易在正確的時間睡覺和吃飯，從而推動市場增長。 此外，世界各地人們可支配收入的增加正在帶來生活方式的改變。 結果，快餐變得更受歡迎。 結果，垃圾食品的消費量增加，導致體內膽固醇水平失衡。 這可能會增加對該藥物的需求，並推動菸鹼醯胺嘌呤二核甘酸 (NAD) 市場的增長。 NAD 也可以由菸酸和色氨酸產生。 另一方面，NAD 可用於治療大多數癌症。 因此，全球心血管疾病患病率的增加將導致對菸鹼醯胺嘌呤二核甘酸（NAD）的需求增加，從而推動菸鹼醯胺嘌呤二核甘酸（NAD）市場的增長。

但是，旨在防止不利健康影響的政府劑量法規預計會限制行業增長。

市場細分：全球菸鹼醯胺嘌呤二核甘酸市場份額最高的是食品級

食品級類別佔據了最高的銷售份額，預計將保持這一地位。 由於 NAD 的抗氧化特性，其在食品和飲料行業的使用已顯著擴大，增加了對食品級 NAD 的需求。 NAD 作為許多重要生物過程的底物和輔助因子發揮著重要作用，例如 DNA 修復和表觀遺傳調控基因表達，並有望進一步推動市場。

另一方面，預計醫藥品類在預測期內將大幅擴張。 NAD 作為生產眾多保健藥物的活性成分的流行增加了製藥公司對 NAD 的需求。 由於 NAD 增強藥物在修復 DNA 損傷和修飾以預防阿爾茨海默病、癡呆和帕金森氏病等疾病方面的效率，預計製藥行業對 NAD 的需求量很大。

地理滲透：亞太地區將在預測期內佔據主導地位

由於 NAD 在營養品和補充劑製造中的廣泛適用性及其在製藥領域的日益普及，亞太地區可能會成為該行業的重要樞紐。 此外，對改進慢性病疫苗接種的需求不斷增加以及市場參與者的強大存在被推測將刺激該地區的市場增長。 預計北美將在 2021 年佔據重要的市場收入份額。 消費者對健康益處的認識不斷提高是幫助推動該地區市場增長的關鍵因素。 此外，該地區心血管疾病的增加將創造對 NAD 的需求。

內容

第1章調查方法及範圍

  • 調查方法
  • 市場範圍

第2章主要趨勢與發展

第 3 章執行摘要

  • 按等級劃分的市場細分
  • 按應用劃分的市場細分
  • 按地區劃分的市場細分

第4章市場動態

  • 市場影響因素
    • 司機
    • 約束因素
    • 商機
  • 影響分析

第5章行業分析

  • 波特的五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章按等級

  • 食品級
  • 醫藥級
  • 其他

第八章應用

  • 膳食補充劑
  • 醫藥
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 競爭戰略分析
  • 市場情況/份額分析
  • 併購分析

第11章公司簡介

  • Bontac 生物工程
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • HiMedia Laboratories
  • NutriScience Innovations, LLC
  • Nutrifoods
  • Bontac Bio-engineering（shenzhen）co., ltd
  • Krackeler Scientific
  • Shandong Lankang Bio-Technology Co., Ltd.
  • Shenzhen Hygieia Biotechnology Co., Ltd

第12章 DataM

簡介目錄
Product Code: DMFB6040

Market Overview

The pyridine nucleotide nicotinamide adenine dinucleotide (NAD+) is a critical cofactor and substrate for several essential cellular processes, including DNA repair, epigenetically modulated gene expression, intracellular calcium signaling, and immunological functions. As suggested by its name, it comprises two nucleotides, one with an adenine base and the other with a nicotinamide base. Their shared phosphate groups bind them together. NAD generally comes in two forms: oxidized and reduced, denoted by NAD + and NADH abbreviations. NAD can also be used as a critical supplemental anti-aging medication. One of the most well-known NAD supplements in contemporary biological research is NADH, a mitochondrial hormone that lengthens cells' life cycles (anti-aging). NAD + is also primarily used in catabolic pathways, such as glycolysis, which breaks down energy molecules to create ATP. All living cells use the coenzyme nicotinamide adenine dinucleotide for their respiratory processes (NAD).

The global nicotinamide adenine dinucleotide market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 11.25 % during the forecast period (2022-2029)

Market Dynamics: Increasing consumers health awareness towards NAD drives market expansion

The market's growth is fueled by the use of NAD, making it easier to sleep and eat at the proper times. Additionally, the rise in disposable income among people around the world has brought about lifestyle changes. This has increased the popularity of fast food. As a result, increased consumption of junk food has brought an imbalance in the body's cholesterol levels. This will probably increase the demand for medications and fuel the growth of the Nicotinamide Adenine Dinucleotide (NAD) market. NAD can also be produced from nicotinic acid or tryptophan. On the other hand, NAD can be used to treat most cancers. Therefore, the demand for nicotinamide adenine dinucleotide (NAD) will rise as the prevalence of cardiovascular diseases increases globally, fueling the growth of the nicotinamide adenine dinucleotide (NAD) market.

However, government dosage regulations intended to prevent adverse health effects are predicted to limit industry growth.

Market Segmentation: Food grade segment accounted for the highest share in global nicotinamide adenine dinucleotide market

The highest revenue share was taken by the food grade category, and it is anticipated that it will hold that position for the anticipated amount of time. Because of NAD's antioxidant properties, its use in the food and beverage industry has grown significantly, which has raised the demand for NAD of the food grade. It is anticipated that NAD's significant role as a substrate and cofactor for numerous vital biological processes, including DNA repair and epigenetically controlled gene expression, will further drive the market.

On the other hand, over the forecast period, the pharmaceuticals category is expected to expand significantly. The popularity of NAD as an active ingredient in the production of numerous health medications has increased demand for NAD among pharmaceutical companies. There is anticipated to be a sizable demand for NAD in the pharmaceutical industry due to the efficiency of NAD-boosting medications in repairing DNA damage and modifications to prevent diseases like Alzheimer's disease, dementia, and Parkinson's disease.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period

Asia Pacific region may emerge as a major hub for this industry owing to the wide applicability of NAD in manufacturing nutrition and supplementation together with its growing adoption in the pharma sector. Additionally, increasing demand for improving immunization to chronic diseases, along with the strong presence of market players, is estimated to stimulate regional market growth. North America is expected to hold a significant market revenue share in the year 2021. Growing awareness related to the health benefits among the consumer is the key factor that helps in boosting the market growth in the region. In addition, a growing number of cardiovascular diseases in the region will create a demand for the NAD.

Competitive Landscape:

There are several established participants in the industry and local manufacturers; hence, the market is fragmented. The nicotinamide adenine dinucleotide industry is expected to see several product innovation initiatives, strategic partnerships, mergers, and acquisitions by industry participants. Some of the key players in the industry are Bontac Bioengineering, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., F. Hoffmann-La Roche Ltd, HiMedia Laboratories, NutriScience Innovations, LLC, Nutrifoods, Bontac Bio-engineering(shenzhen)co., ltd, Krackeler Scientific, Shandong Lankang Bio-Technology Co., Ltd, and Shenzhen Hygieia Biotechnology Co., Ltd. For instance, On December 7, 2021, Biocon Limited, an innovation-led global biopharmaceutical company, partnered with Tabuk Pharmaceutical Manufacturing Company, a leading pharmaceutical company in the Middle East and North Africa (MENA), to commercialize select specialty products in the Middle East. The products' marketing authorization will be held by Tabuk Pharmaceuticals, which will also be in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations.

On the other hand, on 29 December 2021, Novo Nordisk acquired Dicerna Pharmaceuticals. With the completion of the merger, Dicerna became a wholly-owned subsidiary of Novo Nordisk. The common stock of Dicerna will not be disclosed on listed or traded on the Nasdaq Global Select Market.

COVID-19 Impact: Positive impact on the global nicotinamide adenine dinucleotide market

The COVID-19 pandemic prompted business owners to protect and maintain their supply chains to meet the growing demand for their products. However, improvements in NAD supplements and products, along with growing knowledge of the benefits of the products, supported product deployment in the cosmetics and pharmaceutical sectors. In order to stay ahead of the competition and drive overall business growth, key market players in the nicotinamide adenine dinucleotide market spend a lot of time expanding their product portfolios and conducting extensive R&D projects. The outcomes of a clinical investigation on the security and tolerability of the NAD + precursor nicotinamide riboside was released in October 2022 by the dietary supplement expert ChromaDex (NR). The results showed that NR could increase NAD + levels, making it an innovative treatment for heart failure with a lower ejection fraction.

The global nicotinamide adenine dinucleotide market report would provide an access to approximately 53 market data tables, 43 figures and 96 pages.

Table of Contents

1. Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Grade
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Grade

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Type
    • 7.1.2. Market attractiveness index, By Type
  • 7.2. Food Grade *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Pharmaceutical Grade
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application
    • 8.1.2. Market attractiveness index, By Application
  • 8.2. Dietary Supplements *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Pharmaceuticals
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. Bontac Bioengineering *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • 11.3. F. Hoffmann-La Roche Ltd
  • 11.4. HiMedia Laboratories
  • 11.5. NutriScience Innovations, LLC
  • 11.6. Nutrifoods
  • 11.7. Bontac Bio-engineering(shenzhen)co., ltd
  • 11.8. Krackeler Scientific
  • 11.9. Shandong Lankang Bio-Technology Co., Ltd.
  • 11.10. Shenzhen Hygieia Biotechnology Co., Ltd
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us